Einloggen
E-Mail
Passwort
Merken
Passwort vergessen?
Werden Sie kostenlos Mitglied
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON

INCYTE CORPORATION

(INCY)
  Bericht
verzögerte Kurse. Verzögert Nasdaq - 29.07. 22:00:00
77.4 USD   -0.78%
28.07.DGAP-NEWS : MorphoSys AG berichtet über die -3-
DJ
28.07.DGAP-NEWS : MorphoSys AG berichtet über die -2-
DJ
26.07.Morphosys wird wegen Monjuvi zurückhaltender bei Umsatzprognose
DP
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-NewsMarketScreener Analysen
Nachrichten in anderen Sprachen über INCYTE CORPORATION
29.07.ELI LILLY AND : Incyte Get Expanded Emergency Use Approval for Baricitinib as Mo..
29.07.ELI LILLY : EUA élargie pour le baricitinib dans la Covid-19
29.07.Fda Broadens Existing Emergency Use of Lilly and Incyte's Baricitinib in Pati..
29.07.Lilly, Incyte Get Emergency Use Authorization for Covid-19 Treatment as Monot..
28.07.PRESS RELEASE : MorphoSys AG Reports Second -2-
28.07.PRESS RELEASE : MorphoSys AG Reports Second Quarter and First Half 2021 Results
28.07.INCYTE : Announces Progress on Global Responsibility Initiatives and Sets Corpor..
26.07.DGAP-ADHOC : Ad-hoc: MorphoSys AG to update financial guidance for 2021 and redu..
23.07.INCYTE : Discloses FDA Request for More Data for Biologics License Application T..
23.07.INCYTE : Provides Regulatory Update on Retifanlimab for the Treatment of Certain..
23.07.Incyte Corporation Provides Regulatory Update on Retifanlimab for the Treatme..
23.07.DGAP-NEWS : Il settore delle biotecnologie -2-
23.07.PRESS RELEASE : Solid second quarter for the -2-
21.07.NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
19.07.INCYTE : GvHD Hub continues to enhance global knowledge of graft-versus-host dis..
16.07.Health Care Climbs On Defensive Bias -- Health Care Roundup
16.07.ELI LILLY AND : Incyte Say FDA May Miss Target Action Data for Baricitinib
16.07.ELI LILLY AND : Incyte Say FDA to Miss PDUFA Target Action Data for Baricitinib
16.07.Eli Lilly and Company and Incyte Corporation Provide Update on Supplemental N..
15.07.INCYTE : to Report Second Quarter Financial Results
14.07.INCYTE : Reports 'Extremely Compelling' Results in Phase 3 Trial of Ruxolitinib ..
14.07.INCYTE : Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxo..
14.07.Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Rux..
14.07.BRIACELL THERAPEUTICS : Opens Enrollment for Breast Cancer Study With Incyte
09.07.INNOVENT BIOLOGICS : Chinese Regulators Accept Innovent Bio's New Drug Applicati..
07.07.INSIDER TRENDS : Insider at Incyte Awarded Stock Portion of Which is Sold for Ta..
07.07.INSIDER TRENDS : Incyte Insider Gets Stock Award Makes Tax Sale with Portion, In..
07.07.INSIDER TRENDS : Insider at Incyte Awarded Shares Uses Portion to Pay Taxes, Red..
07.07.INSIDER TRENDS : Incyte Insider Receives Stock Award Uses Portion to Pay Taxes, ..
07.07.INSIDER TRENDS : Incyte Insider Awarded Stock Portion of Which is Sold for Taxes..
07.07.INSIDER TRENDS : Incyte Insider Gets Stock Award Sells Portion for Taxes Scaling..
07.07.INSIDER TRENDS : Incyte Insider Receives Shares Award Sells Portion for Taxes
07.07.INSIDER TRENDS : Insider at Incyte Gets Shares Award Sells Portion for Taxes
02.07.INCYTE : INCY) sees Significant Insider Selling Continuing
01.07.INCYTE : Insider at Incyte (INCY) Makes Significant Sale of Stock
30.06.INSIDER TRENDS : Incyte Insider Makes Tax Sale Extends 90-Day Selling Trend
29.06.EU picks antibody treatments, arthritis drug as preferred COVID-19 therapies
25.06.INCYTE : Pipeline Bears 'Muted' Enthusiasm on Competition, Commercial Execution ..
25.06.INCYTE : MorphoSys Receive Positive Opinion for Tafasitamab Marketing Authorizat..
25.06.PRESS RELEASE : MorphoSys and Incyte Announce -2-
25.06.PRESS RELEASE : MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasita..
25.06.Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combin..
25.06.INCYTE CORPORATION(NASDAQGS : INCY) added to Russell 3000 Value Index
25.06.INCYTE CORPORATION(NASDAQGS : INCY) added to Russell Midcap Value Index
25.06.INCYTE CORPORATION(NASDAQGS : INCY) added to Russell 1000 Value Index
25.06.INCYTE CORPORATION(NASDAQGS : INCY) added to Russell 1000 Value-Defensive Index
25.06.INCYTE CORPORATION(NASDAQGS : INCY) added to Russell 1000 Growth-Defensive Index
25.06.INCYTE CORPORATION(NASDAQGS : INCY) added to Russell 1000 Defensive Index
25.06.INCYTE CORPORATION(NASDAQGS : INCY) added to Russell 3000E Value Index
24.06.STREET COLOR : Incyte Announced ODAC Voted 13-4 to Defer Regulatory Decision on ..
24.06.INCYTE : Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meet..
12.06.INCYTE : Announces Updated Data for Ruxolitinib Cream Accepted for Presentation ..
11.06.Vertex, Incyte fall; Precigen, Magnachip rise
11.06.Stocks Retreat Midday Amid Inflation Worries
11.06.MIDDAY REPORT : Wall Street Retreats Midday Amid Inflation Worries
11.06.SECTOR UPDATE : Health Care Stocks Slipping Ahead of Friday's Market Open
11.06.INCYTE : Review Period for Incyte's Ruxolitinib New Drug Application Extended by..
11.06.INCYTE : Announces U.S. FDA Has Extended the New Drug Application Review Period ..
11.06.Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period..
08.06.INCYTE : Says FDA Extends Supplemental New Drug Application Review Period for Ru..
08.06.INCYTE : Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib ..
08.06.Incyte Corporation Announces U.S. Food and Drug Administration Extends sNDA R..
07.06.INCYTE : MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND St..
06.06.INCYTE : et MorphoSys annoncent les résultats à trois ans de l'étude L-MIND de P..
04.06.Germany's MorphoSys, Incyte Say Three-Year Data Backing Tafasitamab Combo in ..
04.06.INCYTE : and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of ..
04.06.Incyte and MorphoSys US, Inc. Announce Three-Year Results from Phase 2 L-MIND..
04.06.PRESS RELEASE : MorphoSys and Incyte Announce -3-
04.06.PRESS RELEASE : MorphoSys and Incyte Announce -2-
04.06.PRESS RELEASE : MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-..
04.06.PRESS RELEASE : Novartis announces Tabrecta(R) first published overall survival ..
03.06.BRIACELL THERAPEUTICS : Reports 12.0 Months Overall Survival Benefit in Advanced..
02.06.INCYTE : OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness ..
27.05.INCYTE : AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN (Form 8-K)
27.05.INCYTE CORP : Change in Directors or Principal Officers, Submission of Matters t..
1  2  3  4  5  6  7  8  9  10Weiter
Offizielle Publikationen
15.07.Zeitliche Planung 
01.06.Bericht 
26.05.SEC Filing 8K 
26.05.Bericht 
14.05.Bericht 
04.05.Pressemitteilung 
Anstehende Termine für INCYTE CORPORATION